trending Market Intelligence /marketintelligence/en/news-insights/trending/vixmctrf237wkkqw8aatpq2 content esgSubNav
In This List

Focused ultrasound for surgery; Takeda braces for revenue hit ahead of Shire buy


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Focused ultrasound for surgery; Takeda braces for revenue hit ahead of Shire buy

Here are the editors' top picks for the week ended May 18.

Ultrasound tech could make scalpel redundant in future brain, cancer surgeries

"Focused ultrasound is the most powerful sound you will never hear, but it's a sound that can save your life," Neal Kassell, founder and chairman of the Focused Ultrasound Foundation, told S&P Global Market Intelligence.

Calif., Ohio initiatives seek to cap kidney dialysis charges

A national healthcare union is pushing ballot initiatives in California and Ohio to limit the amount that centers can charge for dialysis treatment at 15% more than providers' costs.

As Ebola cases mount, world health officials convene emergency meeting

The latest Ebola outbreak has reached an urban center, raising international concern and sparking an emergency meeting of the World Health Organization.

HHS chief tells pharma Medicare merger coming, play on prices or be forced to

Drugmakers need to come to terms with the plan to merge the separate ways the government pays for pills versus injectable medicines and come up with solutions on lowering prices or the industry will be forced to do so, the U.S. health chief said.

Novartis general counsel to exit over Trump lawyer deal dust-up

Felix Ehrat, group general counsel at the Swiss drugmaker, is stepping down after details emerged on the $1.2 million contract the company struck with President Donald Trump's lawyer Michael Cohen.

Medicare, Medicaid make long-awaited updates to drug price dashboard

The Centers for Medicare and Medicaid Services made some long-awaited updates to the agency's online databases that provide Americans information about the government's spending on prescription drugs — changes Democrats said were long overdue.

Drug discount program for hospitals needs more scrutiny, US Senate panel told

Officials from two federal government watchdog agencies urged a U.S. Senate committee to increase oversight of the controversial 340B drug discount program for hospitals.

FDA aims to deter, not shame, system-gamers by unmasking them, chief says

The U.S. Food and Drug Administration plans to start identifying brand-name drugmakers that have attempted to game the system by using certain tactics to block generic competitors from entering the American market, the head of the agency said.

Capitol Checkup: Novartis deal questioned; drug price disclosure mixed reactions

Two U.S. senators are probing Novartis AG's $1.2 million deal with President Donald Trump's lawyer, and a proposal for the Food and Drug Administration to look into its authority to require disclosure of drug prices in TV ads got mixed reactions.

Trump targets PBMs, TV ads, foreign 'freeloaders' in drug price strategy

President Trump took aim at pharmacy benefit managers, consumer drug advertising and what he called "foreign freeloaders" in his strategy to lower the costs of prescription medicines in the U.S.

Drugmakers tout 'golden age' as they brace for Trump action on prices

The lobbying group representing the world's biggest drugmakers touted a "golden age for medicine" at the May 10 FT US Healthcare & Life Sciences Summit as the industry braced for President Trump to unveil his plan to lower drug costs.

Earnings coverage

Takeda braces for FY'19 revenue crunch ahead of Shire acquisition

According to the CFO, the company plans to soften the anticipated growth decline by boosting its noncore asset disposals during the fiscal year ending March 31, 2019.

Merck KGaA seeking partners to develop drug pipeline

Merck KGaA is looking for partnerships to develop some of its pipeline drugs even as sales are starting to flow in from new products.

Japan's Eisai taps partnership model to expand drug innovation

Tokyo-based Eisai Co. Ltd., which has recently teamed up with Biogen Inc., Merck & Co. Inc. and others, said it will continue to rely on partnerships to fuel innovation.